Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is poised for success in the chronic low back pain market with their Nociscan technology, as demonstrated by their Q1 FY26 EPS beat, ample cash runway through 2H2027, and strong investments in sales and R&D. With the launch of their CLARITY trial in 2025 and rising adoption of Nociscan by payors and providers, Aclarion's huge US market opportunity in the $400 million range is well within reach. However, risks to attainment of their share price target include potential balance sheet/liquidity risks and slower enrollment in the CLARITY trial.

Bears say

Aclarion is facing challenges in their CLARITY trial with initial data being released in Q4 2026 and only one private practice site being added so far. Additionally, although Aclarion has a strong IP portfolio with 64 issued and pending patents, it is currently a commercially-driven company and may face obstacles in proving the efficacy of Nociscan to physicians and payors in the highly competitive healthcare technology market. Furthermore, with uncertain timelines for trial results and potential hurdles in gaining widespread adoption, there is a risk that Aclarion's stock may face downward pressure.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.